$VXRT
Vaxart, Inc.

2023 Q2 Form 10-Q Financial Statement

#000143774923012560 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1
Revenue $1.358M $675.0K
YoY Change 694.12%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.598M $6.625M
YoY Change -39.94% -0.5%
% of Gross Profit
Research & Development $18.81M $19.62M
YoY Change -5.59% 7.8%
% of Gross Profit
Depreciation & Amortization $944.0K $2.062M
YoY Change 111.19% 457.3%
% of Gross Profit
Operating Expenses $24.41M $26.25M
YoY Change -16.54% 5.57%
Operating Profit -$23.05M -$25.57M
YoY Change -21.18% 3.21%
Interest Expense $711.0K $642.0K
YoY Change 352.87% 1734.29%
% of Operating Profit
Other Income/Expense, Net -$188.0K -$178.0K
YoY Change -41.8% -47.65%
Pretax Income -$22.53M -$25.11M
YoY Change -23.4% 0.12%
Income Tax $19.00K $29.00K
% Of Pretax Income
Net Earnings -$22.55M -$25.14M
YoY Change -23.38% 0.16%
Net Earnings / Revenue -1660.53% -3724.44%
Basic Earnings Per Share -$0.16 -$0.19
Diluted Earnings Per Share -$0.16 -$0.19
COMMON SHARES
Basic Shares Outstanding 135.6M 135.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $67.91M $71.81M
YoY Change -47.58% -51.37%
Cash & Equivalents $43.30M $48.40M
Short-Term Investments $24.63M $23.38M
Other Short-Term Assets $3.327M $3.755M
YoY Change -59.74% -41.7%
Inventory
Prepaid Expenses
Receivables $29.00K $264.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $71.26M $75.83M
YoY Change -48.29% -50.82%
LONG-TERM ASSETS
Property, Plant & Equipment $13.92M $14.37M
YoY Change 49.08% 88.4%
Goodwill $4.508M $4.508M
YoY Change 0.18% 0.18%
Intangibles $4.654M $4.837M
YoY Change -53.22% -52.97%
Long-Term Investments
YoY Change
Other Assets $1.508M $2.460M
YoY Change -72.47% 58.1%
Total Long-Term Assets $51.39M $54.02M
YoY Change 17.75% 16.93%
TOTAL ASSETS
Total Short-Term Assets $71.26M $75.83M
Total Long-Term Assets $51.39M $54.02M
Total Assets $122.7M $129.9M
YoY Change -32.41% -35.2%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.199M $3.882M
YoY Change -16.14% -3.36%
Accrued Expenses $6.050M $6.977M
YoY Change -28.32% 36.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $900.0K $900.0K
YoY Change -35.71% 12.5%
Total Short-Term Liabilities $13.88M $15.68M
YoY Change -12.83% 42.12%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $262.0K $246.0K
YoY Change 30.35% 32.26%
Total Long-Term Liabilities $262.0K $246.0K
YoY Change 30.35% 32.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.88M $15.68M
Total Long-Term Liabilities $262.0K $246.0K
Total Liabilities $37.58M $40.10M
YoY Change -2.03% 17.89%
SHAREHOLDERS EQUITY
Retained Earnings -$374.8M -$352.2M
YoY Change 36.85% 44.1%
Common Stock $459.9M $442.1M
YoY Change 10.19% 7.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $85.07M $89.75M
YoY Change
Total Liabilities & Shareholders Equity $122.7M $129.9M
YoY Change -32.41% -35.2%

Cashflow Statement

Concept 2023 Q2 2023 Q1
OPERATING ACTIVITIES
Net Income -$22.55M -$25.14M
YoY Change -23.38% 0.16%
Depreciation, Depletion And Amortization $944.0K $2.062M
YoY Change 111.19% 457.3%
Cash From Operating Activities -$17.47M -$24.46M
YoY Change -32.54% -2.6%
INVESTING ACTIVITIES
Capital Expenditures $454.0K $1.239M
YoY Change -119.52% -7.95%
Acquisitions
YoY Change
Other Investing Activities -$1.129M $26.70M
YoY Change -82.76% 425.8%
Cash From Investing Activities -$1.583M $25.46M
YoY Change -82.16% 582.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 13.90M $1.420M
YoY Change 389.68% 36.54%
NET CHANGE
Cash From Operating Activities -17.47M -$24.46M
Cash From Investing Activities -1.583M $25.46M
Cash From Financing Activities 13.90M $1.420M
Net Change In Cash -5.157M $2.421M
YoY Change -83.85% -111.9%
FREE CASH FLOW
Cash From Operating Activities -$17.47M -$24.46M
Capital Expenditures $454.0K $1.239M
Free Cash Flow -$17.92M -$25.70M
YoY Change -23.96% -2.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15683000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17921000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19172000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19477000 usd
CY2023Q1 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
4997000 usd
CY2022Q4 vxrt Liability Related To Sale Of Future Royalties Noncurrent
LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
5621000 usd
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
246000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
231000 usd
CY2023Q1 us-gaap Liabilities
Liabilities
40098000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
43250000 usd
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
135610869
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
135597316
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
134199429
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
134199429
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
13553
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
0
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
103000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
314000 usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-35285
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
59-1212264
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
170 Harbor Way, Suite 300
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
550-3500
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
VXRT
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
135597316
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48434000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46013000 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
23377000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
49704000 usd
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
264000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20000 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3755000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3714000 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
75830000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
99451000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14373000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15585000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27843000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25715000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4837000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5020000 usd
CY2023Q1 us-gaap Goodwill
Goodwill
4508000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
4508000 usd
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2460000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3568000 usd
CY2023Q1 us-gaap Assets
Assets
129851000 usd
CY2022Q4 us-gaap Assets
Assets
153847000 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3882000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5514000 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1603000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2000000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6977000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8084000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2344000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2228000 usd
CY2023Q1 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
877000 usd
CY2022Q4 vxrt Liability Related To Sale Of Future Royalties Current
LiabilityRelatedToSaleOfFutureRoyaltiesCurrent
95000 usd
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
14000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
13000 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
442068000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
437992000 usd
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
10000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
-0 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-352249000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-327109000 usd
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-70000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-299000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
89753000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
110597000 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
129851000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153847000 usd
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
675000 usd
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
85000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19622000 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18203000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6625000 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6658000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
26247000 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
24861000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-25572000 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-24776000 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
642000 usd
CY2022Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
35000 usd
CY2023Q1 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
178000 usd
CY2022Q1 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
340000 usd
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3000 usd
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0 usd
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25111000 usd
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25081000 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000 usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25140000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25101000 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135213196
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125795255
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25140000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25101000 usd
CY2023Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
229000 usd
CY2022Q1 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-235000 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24911000 usd
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25336000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
110597000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1430000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2647000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
10000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
229000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25140000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
89753000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
187531000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
992000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
48000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3130000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-235000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25101000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
166365000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25140000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25101000 usd
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2062000 usd
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1131000 usd
CY2023Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
144000 usd
CY2022Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
-36000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2647000 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3130000 usd
CY2023Q1 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
178000 usd
CY2022Q1 vxrt Noncash Interest Expense On Liability
NoncashInterestExpenseOnLiability
340000 usd
CY2023Q1 vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
20000 usd
CY2022Q1 vxrt Noncash Revenue Related To Sale Of Future Royalties
NoncashRevenueRelatedToSaleOfFutureRoyalties
71000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
244000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1067000 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4498000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-270000 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
113000 usd
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-397000 usd
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4199000 usd
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-183000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24460000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25113000 usd
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1239000 usd
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1346000 usd
CY2023Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
-0 usd
CY2022Q1 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8522000 usd
CY2023Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
26700000 usd
CY2022Q1 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
13600000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25461000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
3732000 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1430000 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
992000 usd
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
10000 usd
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
-0 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
48000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1420000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1040000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2421000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20341000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46013000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143745000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48434000 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123404000 usd
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
296000 usd
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
125000 usd
CY2023Q1 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
246000 usd
CY2022Q1 us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
505000 usd
CY2023Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
71800000 usd
CY2023Q1 vxrt Reduction In Workforce Percentage
ReductionInWorkforcePercentage
0.27 pure
CY2023Q1 us-gaap Severance Costs1
SeveranceCosts1
732000 usd
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"/> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"><b>Use of Estimates</b> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"/> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Concentration of Credit Risk</b> – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, restricted cash and available-for-sale investments. The Company places its cash, cash equivalents, restricted cash and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash, cash equivalents and restricted cash to the extent such amounts are in excess of the federally insured limits. Losses incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;"/><p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b/></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any <em style="font: inherit;">one</em> corporate issuer or sector and establishing a minimum allowable credit rating.</p>
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5080000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5080000 usd
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
71881000 usd
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
70000 usd
CY2023Q1 vxrt Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
71811000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48434000 usd
CY2023Q1 us-gaap Short Term Investments
ShortTermInvestments
23377000 usd
CY2023Q1 us-gaap Long Term Investments
LongTermInvestments
0 usd
CY2022Q4 us-gaap Investments And Cash
InvestmentsAndCash
96016000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
299000 usd
CY2022Q4 vxrt Investments And Cash Fair Value Disclosure
InvestmentsAndCashFairValueDisclosure
95717000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46013000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
49704000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
0 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48400000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46000000.0 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
1600000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
2000000.0 usd
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18539000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
18857000 usd
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4166000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3272000 usd
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14373000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15585000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
27800000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25700000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
243000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
60000 usd
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
4837000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5020000 usd
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
183000 usd
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
338000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
548000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
731000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
731000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
731000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
731000 usd
CY2023Q1 vxrt Finitelived Intangible Asset Expected Amortization After Year Four
FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour
1365000 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
4837000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
4500000 usd
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2865000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3112000 usd
CY2023Q1 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
1497000 usd
CY2022Q4 vxrt Accrued Clinical And Manufacturing Expenses Current
AccruedClinicalAndManufacturingExpensesCurrent
2413000 usd
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
524000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
691000 usd
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2091000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1868000 usd
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6977000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8084000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2000000.0 usd
CY2023Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1600000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2000000.0 usd
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.098 pure
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
3117000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
4275000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
4421000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4975000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
5205000 usd
CY2023Q1 vxrt Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
6797000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
28790000 usd
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7274000 usd
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
21516000 usd
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2344000 usd
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19172000 usd
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2000000.0 usd
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 usd
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
1510000 usd
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
719000 usd
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
21000 usd
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
118000 usd
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
511000 usd
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
265000 usd
CY2023Q1 us-gaap Lease Cost
LeaseCost
2042000 usd
CY2022Q1 us-gaap Lease Cost
LeaseCost
1102000 usd
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 vxrt Common Stock Increase In Shares Authorized
CommonStockIncreaseInSharesAuthorized
100000000
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q1 us-gaap Dividends
Dividends
0 usd
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29582129
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29635697
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
227434
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
12074692
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
14725261
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.48
CY2023Q1 vxrt Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants
10071992
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
6960943
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.78
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
-0
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2023Q1 vxrt Sharebased Compensation Arrangement By Sharebased Payment Award Options Released In Period
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsReleasedInPeriod
-0
CY2023Q1 vxrt Sharebased Compensation Arrangements By Sharebased Payment Award Options Released In Period Weighted Average Exercise Price
SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsReleasedInPeriodWeightedAverageExercisePrice
0
CY2023Q1 vxrt Share Based Compensation Arrangement By Share Based Payment Award Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeited
1887633
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1726202
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.43
CY2023Q1 vxrt Share Based Compensation Arrangement By Share Based Payment Award Canceled
ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled
650435
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
654783
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
3.72
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4540768
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19305219
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.09
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.78
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.48
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2647000 usd
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3130000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-25140000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25101000 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
135213196
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
125795255
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.19
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16315008
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11147062

Files In Submission

Name View Source Status
0001437749-23-012560-index-headers.html Edgar Link pending
0001437749-23-012560-index.html Edgar Link pending
0001437749-23-012560.txt Edgar Link pending
0001437749-23-012560-xbrl.zip Edgar Link pending
ex_470054.htm Edgar Link pending
ex_470055.htm Edgar Link pending
ex_470056.htm Edgar Link pending
ex_513186.htm Edgar Link pending
ex_513187.htm Edgar Link pending
ex_513188.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img17.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
logo.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vaxart01.jpg Edgar Link pending
vxrt-20230331.xsd Edgar Link pending
vxrt20230331_10q.htm Edgar Link pending
vxrt-20230331_cal.xml Edgar Link unprocessable
vxrt-20230331_def.xml Edgar Link unprocessable
vxrt-20230331_lab.xml Edgar Link unprocessable
vxrt-20230331_pre.xml Edgar Link unprocessable
vxrt20230331_10q_htm.xml Edgar Link completed